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The development of a drug-resistant cell line can take from 3 to 18 months. However, lit-
tle is published on the methodology of this development process. This article will discuss
key decisions to be made prior to starting resistant cell line development; the choice of
parent cell line, dose of selecting agent, treatment interval, and optimizing the dose of
drug for the parent cell line. Clinically relevant drug-resistant cell lines are developed by
mimicking the conditions cancer patients experience during chemotherapy and cell lines
display between two- and eight-fold resistance compared to their parental cell line. Doses
of drug administered are low, and a pulsed treatment strategy is often used where the
cells recover in drug-free media. High-level laboratory models are developed with the aim
of understanding potential mechanisms of resistance to chemotherapy agents. Doses of
drug are higher and escalated over time. It is common to have difficulty developing stable
clinically relevant drug-resistant cell lines. A comparative selection strategy of multiple cell
lines or multiple chemotherapeutic agents mitigates this risk and gives insight into which
agents or type of cell line develops resistance easily. Successful selection strategies from
our research are presented. Pulsed-selection produced platinum or taxane-resistant large
cell lung cancer (H1299 and H460) and temozolomide-resistant melanoma (Malme-3M
and HT144) cell lines. Continuous selection produced a lapatinib-resistant breast cancer
cell line (HCC1954).Techniques for maintaining drug-resistant cell lines are outlined includ-
ing; maintaining cells with chemotherapy, pulse treating with chemotherapy, or returning to
master drug-resistant stocks. The heterogeneity of drug-resistant models produced from
the same parent cell line with the same chemotherapy agent is explored with reference
to P-glycoprotein. Heterogeneity in drug-resistant cell lines reflects the heterogeneity that
can occur in clinical drug resistance.
Keywords: chemotherapy, cancer, drug-resistance, cell lines, selection strategy
INTRODUCTION AND HISTORICAL PERSPECTIVE
The development of chemotherapy drug-resistant cancer cell lines
is a long established approach for investigating the mechanisms
of cytotoxicity and resistance to chemotherapy agents. One of the
first publications to describe the development of an anti-cancer
drug-resistant in vitro model, which exhibited acquired resistance
Abbreviations: 5-FU, fluorouracil; ADR, adriamycin; AUC, area under concentra-
tion time curve; CHL, chlorambucil; CIS, cisplatin; CR, complete response; CSC,
cancer stem cells; CYC, cyclophosphamide; DNR, daunorubicin; DOCE, docetaxel;
DOX, doxorubicin; EPI, epirubicin; ETO, etoposide; GFR, glomerular filtration
rate; IC50, 50% inhibitory concentration; IFO, ifosfamide; IV, intravenous; MEL,
melphalan; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NR, no response; OX, oxaliplatin; PARP, poly (ADP-ribose) polymerase; PD, pro-
gressive disease; P-gp, P-glycoprotein; PR, partial response; PRED, prednimustine;
RAD, radiation; SCLC, small cell lung cancer; TAX, paclitaxel; THI, thiotepa; UNK,
unknown; VINC, vincristine; VIND, vindesine.
to a chemotherapy drug, was published in 1970 (1). Resistant
cell lines were developed from parental Chinese hamster cells
using a stepwise increase in treatment dose with actinomycin
D. This induced 2500-fold greater resistance to the drug than
that observed in the parental cells. These resistant cell lines were
also cross resistant to other chemotherapy drugs such as vin-
blastine and daunorubicin. Some earlier drug-resistant cell lines
were developed in the 1950 and 1960s using in vivo mouse mod-
els, including models resistant to methotrexate (2, 3), vinblastine,
terephthalanilide (4), and the guanine analog, 8-azaguanine (5).
Publications in this research field usually place little empha-
sis on how the drug-resistant cell lines were established in the
laboratory. The development of drug-resistant cell lines can take
anything from 3 to 18 months in the laboratory and many deci-
sions are taken along this journey. This review summarizes the
major methodological approaches for developing drug-resistant
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cell lines in vitro with reference to the literature and includes
several case studies from our experience.
IC50 VALUES AND FOLD RESISTANCE
Drug-resistant cell models are developed in the laboratory by
repeatedly exposing cancer cells growing in cell culture to
drugs. The surviving daughter resistant cells are then compared
to the parental sensitive cells using combination cell viabil-
ity/proliferation assays such as the MTT (6), acid phosphatase
(6), or clonogenic assays (7). The sensitivity of these paired cell
lines is usually determined by exposing them to a range of drug
concentrations and then assessing cell viability. The IC50 (drug
concentration causing 50% growth inhibition) for these paired cell
lines can be used to determine the increase in resistance known as
fold resistance by the following equation:
Fold Resistance = IC50 of Resistant Cell Line/IC50 of Parental
Cell Line
WHAT IS A CLINICALLY RELEVANT LEVEL OF RESISTANCE?
To determine the level of drug resistance that occurs in the clin-
ical treatment of cancer we can compare cell lines that have been
established from cancer patients before and after chemotherapy
(Table 1) (8–14). The majority of cell lines listed in Table 1
developed from patients post-chemotherapy show a two- to five-
fold increase in resistance to the agents the patients were treated
with, based on a comparison of IC50 values. Three cell lines had
higher levels of resistance but these were still relatively low-level
at ~8–12-fold higher than the parental cells (PEO4, SK-3, and
GLC-16).
CLINICALLY RELEVANT VS. HIGH-LEVEL LABORATORY MODELS
For the purposes of this review we will divide drug-resistant cell
models into two categories: clinically relevant models or high-level
laboratory models. Both types of models have their advantages and
disadvantages for research.
Clinically relevant models are developed with the aim of try-
ing to mimic the conditions cancer patients experience during
chemotherapy. Doses of drug are lower, and a pulsed treatment
strategy is often used where the cells recover in drug-free media.
This mimics the cycles of chemotherapy a patient receives in the
clinic. Disadvantages to clinically relevant models can include
unstable resistance, very low-level resistance, and small mole-
cular changes to detect and analyze. Based on the cell lines
derived from the patients before and after chemotherapy shown
in Table 1; we have defined clinically relevant resistance as a
two- to five-fold increase from the IC50 value of the parent cell
line. Examples of clinically relevant models are shown in Table 2
(15–21).
High-level laboratory models are developed with the aim of
understanding potential mechanisms of toxicity and resistance to
chemotherapy agents. Doses of drug are often high and treatment
doses are escalated over time. Cells are frequently grown contin-
ually in the presence of drug or highly drug-resistant clones are
selected from a mixed population. In some earlier drug-resistant
models, mutagenesis was also induced prior to drug treatment (22,
Table 1 | Cell lines established from cancer patients before and after chemotherapy.
Cancer type Parent cell line
(established)
Chemotherapy
received
Resistant cell line
(established)
Fold resistance to
chemotherapy received
Reference
Lung EBC-2 (18th September
1997)
CIS, IFO, VIND EBC-2/R (4th October
1997)
CIS – 2.3, IFOa – 3.2,
VIND – 0.77
(8)
SK-1 (August 1986) CYC, ADR, ETO, VINC,
RAD
SK-2 (March 1987) ADR – 1.2, ETO – 1.2,
CYCb – 1.3
(10)
CIS, ETO SK-3 (May 1987) CIS – 8.6, ETO – 6.2
TM1 (April 1987) CYC, ADR, ETO, VINC TM2 (September 1987) CYCb – 5.4, ADR – 3.0,
ETO – 3.5
GLC-14 (December 1984) CYC, DOX, ETO GLC-16 (October 1985) DOX – 3.18, ETO – 12.1 (11)
Neuroblastoma KP-N-AY (October 1984) ADR, CIS, CYC, VINC KP-N-AYR (December
1985)
ADR – 3.0, CIS – 2.7 (9)
Ovarian PEO1 (February 1982) CIS, CHL, 5-FU PEO4 (November 1982) CIS – 8.72 (12, 13)
CIS, CHL, 5-FU PEO6 (February 1983) CIS – 4.64 (12, 13)
PEA1 CIS, PRED PEA2 CIS – 4.30 (13, 14)
PEO14 CIS, CHL PEO23 CIS – 4.48 (13, 14)
ADR, adriamycin; CIS, cisplatin; CHL, chlorambucil; CYC, cyclophosphamide; DOX, doxorubicin; ETO, etoposide; 5-FU, fluorouracil; IFO, ifosfamide; RAD, radiation;
PRED, prednimustine; VINC, vincristine; VIND, vindesine.
aUsed 4-hydroperoxy ifosfamide (the active form of ifosfamide).
bUsed 4-hydroperoxycyclophosphamide (the active form of cyclophosphamide).
Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs March 2014 | Volume 4 | Article 40 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McDermott et al. Development of in vitro drug-resistant cancer cells
Table 2 | Different selection strategies and classification of resulting drug-resistant cell lines.
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Cervical KB-3-1 CIS Continuous Stepwise and Whole KBCP10 1152 UNK High-level lab (22, 23)
COL mutagenesis Cloned KB-8-5-11 40 UNK High-level lab (24)
Leukemia CCRF-CEM EPI Pulse Constant Whole CEM/E25 7 UNK Clinically relevant (15, 16)
Continuous Stepwise Whole CEM/E1000 94 8 from E25 High-level lab
K562 DNR Pulse Stepwise Whole K562/DNR 3 2 Clinically relevant (17)
Lung DLKP ADR Continuous Stepwise Whole DLKP-A 322 18 High-level lab (25)
A549 PAC Pulse Constant Whole A549-txl 5.5 2.5 Clinically relevant (18)
SKLU1 SKLU1-txl 5.0 Clinically relevant
SKMES1 PAC SKMES1-txl 24.7 High-level lab
DOCE SKMES1-Txt 29.1 High-level lab
DMS53 PAC DMS53-txl 6.3 Clinically relevant
DOCE DMS53-Txt 1.8 Clinically relevant
DLRP DOCE DLRP-Txt 4.1 Clinically relevant
H69 CIS Pulse Constant Whole H69CIS200 1.5–2 8 Clinically relevant (19, 20)
OX H69OX400
Ovarian IGROV-1 CIS Pulse Stepwise Whole IGROVCDDP 8.41 Clinically relevant (21)
ADR, adriamycin; CIS, cisplatin; DNR, daunorubicin; DOCE, docetaxel; EPI, epirubicin; OX, oxaliplatin; UNK, unknown.
23). High-level models are often more stably resistant and there-
fore easier to maintain in culture for an ongoing research project.
Levels of resistance are often higher and as such molecular changes
associated with the mechanism of resistance are larger and easier to
identify. The disadvantage of these models is the higher the level of
resistance the less relevant the model becomes to the clinic. Exam-
ples of high-level laboratory models are shown in Table 2 (15, 16,
18, 22–25).
PLANNING A SELECTION STRATEGY FOR DRUG-RESISTANT
CELL LINES
CHOICE OF PARENTAL CELL LINE
Choosing a parental cell line is very important as it is the basis of all
the subsequent experiments. The parental cell line should be very
easy to maintain in cell culture as resistant variants usually become
more challenging to grow. Ideally, the researchers performing the
drug-resistant selection in the laboratory should be very familiar
with growing the parental cells. Researchers experienced in grow-
ing a particular cell line will have more of an idea of when the
cells need to be subcultured and when it is best to leave them. This
experience is important when deciding when to subculture cells
recovering from the drug treatment.
It is also important to consider the patient from whom the cell
line is derived. If possible, it is good to choose a chemotherapy
and radiation naïve cell line. Previous treatment with chemother-
apeutic agents and radiation may have already caused changes in
resistance pathways, and increased expression of drug resistance
markers that may not be relevant to the agent being studied. How-
ever, chemotherapy and radiation naïve cell lines are relatively rare.
As an alternative to a chemotherapy naïve cell line, choose a cell
line with a relatively low baseline IC50 value for the drug of interest
as a two- to five-fold increase in resistance will result in an IC50
of the daughter resistant cell line remaining within the clinically
relevant range. Table 3 shows the clinical characteristics of some
commonly used ovarian cancer cell lines as an example of the
kind of information that is available for cell lines [(12, 14, 26–38);
Sikic, personal communication]. In the case of ovarian cancer, the
majority of cell lines commonly used in research are derived from
metastatic ascites, and are not chemonaïve (Table 3).
EXPOSURE TO CHEMOTHERAPY AGENT
The researcher needs to decide what kind of model they are trying
to develop, a clinically relevant model or a high-level laboratory
model. A clinically relevant model is informed by data gathered
from the clinical administration of drug and usually has mini-
mal escalation of the treatment dose. The sky is the limit for a
high-level laboratory model where dose escalation is used exten-
sively to achieve a large fold resistance. However, the solubility of
the selecting agent will be final limiting factor in how much drug
can be applied to cancer cells. Doses that approach the limit of
solubility will not be in the clinically relevant range.
The reality is that most selection strategies start out with a clin-
ically relevant strategy and then are escalated within the clinical
range and escalated further again beyond the clinical dose range
to make a high-level model. The main reasons for this approach
are the stability of the resistance phenotype produced and that
the resistance established in the daughter cell line is statistically
significant when compared to the parent cell line.
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Table 3 | Clinical characteristics of ovarian tumors from which ovarian cell lines were established.
Cell line Original tumor histology Isolated from Treatment received
pre-isolation
Response Reference
59M Endometrioid/clear cell Ascites None N/A (26)
EFO27 Mucinous Solid metastasis None N/A (27)
ES2 Serous/clear cell Primary tumor None N/A [(28); Sikic, personal communication]
FUOV1 Serous Primary tumor None N/A (29)
HEY Serous Peritoneal deposit and xenograft Radiotherapy, radium CR (26, 30)
HOC1 Serous Ascites MEL, CIS, ADR, CYC PR, PR (31, 39)
HOC8 Serous Ascites MEL PR (32, 33)
IGROV-1 Endometrioid/clear cell Primary tumor None N/A (34)
OAW28 Adenocarcinoma Ascites CIS, MEL NR, NR (26)
OAW42 Serous Ascites CIS CR (26)
OC316 Serous Ascites CIS, ETO, CYC, TAX PD, SD (35)
OVCAR3 Serous Ascites CYC, CIS, DOX Unknown (26, 36, 37)
PEA1 Adenocarcinoma Pleural effusion None N/A (14)
PEO1 Serous Ascites CIS, CHL, 5-FU CR (12, 14)
PEO14 Serous Ascites None N/A (14)
SKOV3 Adenocarcinoma Ascites THI Unknown (26)
SNU251 Endometrioid Ascites CYC, ADR, CIS Unknown (38)
ADR, adriamycin; CIS, cisplatin; CHL, chlorambucil; CR, complete response; CYC, cyclophosphamide; DOX, doxorubicin; ETO, etoposide; MEL, melphalan; N/A, not
applicable; NR, no response; PD, progressive disease; PR, partial response; TAX, paclitaxel; THI, thiotepa.
Cell lines are frequently cultured in the presence of antibi-
otics in many laboratories. When establishing a new drug-resistant
model, we recommend not using antibiotics as this does not mimic
the clinical situation, cancer patients are not continually treated
with antibiotics. Resistance mechanisms produced in the presence
of antibiotics may not reflect clinical drug resistance.
Pharmacokinetics and drug stability
In order to produce a clinically relevant model of drug resis-
tance, it is important to research how the chemotherapy agent
is administered in the clinical treatment of cancer. The amount of
chemotherapy administered intravenously (IV) is often expressed
in the units milligrams per square meter. These can be converted
to micrograms per milliliter or micromolar by consulting pharma-
cokinetic studies on the drug where the concentration achieved in
the bloodstream is measured.
Chemotherapy administered by IV is often given in cycles where
the patient receives the drug on a weekly or monthly basis. A
pulsed-selection strategy where the cells are treated with drug and
then the surviving population are allowed to recover in drug-free
media mimics this clinical scenario. Pharmacokinetic studies will
give a broad range of doses achieved in the bloodstream, the high-
est immediately after the bolus of drug is administered to the
patient, this then drops over the next hours and days depending
on the rate of excretion of the drug. This gives a broad dose range
to define the clinical relevance of the dose of drug used in the
development of a drug-resistant model. A higher dose for several
hours could model the bolus of drug, a lower dose for a several days
could model the longer excretion of the drug. Following an intra-
venous bolus injection of 100 mg/m2 cisplatin a peak-plasma level
of ~6µg/mL is reached but this quickly drops to <2µg/mL after
2 h (40) Clearance of cisplatin from the body is triphasic where the
distribution half-life is 13 min, the elimination half-life is 43 min,
and the terminal half-life is 5.4 days (41). After 24 h, 25% of the
initial cisplatin dose has been eliminated from the body with renal
clearance accounting for 90%.
Carboplatin has a similar mechanism of action to cisplatin but
needs a 20–40-fold higher dose to exhibit the same cytotoxicity
as cisplatin. However, only a 10-fold increase in carboplatin dose
is required to reach similar intracellular platinum concentrations
(42). After intravenous bolus injection of 375 mg/m2 carboplatin
peak-plasma levels of ~39µg/mL are achieved, which drops to
9µg/mL within 2 h (43). Clearance of carboplatin has a distribu-
tion half-life of 22 min, an elimination half-life of 116 min, and a
terminal half-life of 5.8 days (44). Clearance of carboplatin from
the body is primarily by the urine as unchanged drug. After 24 h,
90% clearance is achieved. Carboplatin does not have significant
excretion from the renal tubules as seen for cisplatin, instead the
glomerular filtrate accounts for the vast majority of elimination.
For this reason, glomerular filtration rate (GFR) is linearly related
to total renal clearance giving relatively simple pharmacokinetics
for carboplatin. Even at high doses evidence suggests that car-
boplatin has linear pharmacokinetics (45). A formula called the
“Calvert formula” has been derived, which is based on the GFR
and is used to provide a suitable dose for patients in relation to an
area under concentration time curve (AUC) value. AUC is the ratio
of the amount of drug that reaches the systemic circulation and
the clearance of the drug, which correlates to its clinical efficiency
and toxicity. This formula has been validated in a perspective study
(46). Conventional doses of carboplatin administered to patients
generally are aimed at giving an AUC value of between 5 and
7 mg/mL/min.
The amount of chemotherapy administered orally is usually
expressed in the unit milligrams per day. Again pharmacokinetic
Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs March 2014 | Volume 4 | Article 40 | 4
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studies can be used to convert this to a concentration in the
bloodstream. A continuous treatment strategy where the cells are
cultured constantly in the presence of drug can be clinically rel-
evant for an oral drug given daily or twice daily as a relatively
constant amount of the drug is present. Olaparib is a member
of the poly (ADP-ribose) polymerase (PARP) inhibitor class of
drugs and is administered orally. The maximum tolerated dose
of olaparib is 400 mg twice daily. Absorption is rapid and its
peak-plasma concentration is reached within 1–3 h. Plasma levels
then decline biphasically and it has a terminal elimination half-
life of ~5–7 h (47). A phase 1 study on Japanese patients found
that peak-plasma values for a single dose of 400 mg olaparib was
~7µg/mL, which dropped below 0.1µg/mL after 50 h. For a dose
of 400 mg administered twice daily for 15 days, peak-plasma con-
centrations were found to be similar. The half-life of olaparib was
recorded to be between 7 and 11 h across doses ranging from 100
to 400 mg (48).
The chemical stability of drugs used in establishing drug-
resistant cell line models is also an important consideration when
designing a selection strategy. For example, temozolomide an alky-
lating agent used in the treatment of glioblastoma and metastatic
melanoma when in its active state, has a half-life of 25 and 60 min
for the first and second phases (49) whilst docetaxel a microtubule
destabilizing agent has a half-life of 12 h (50). Lapatinib, a dual
EGFR HER2 inhibitor used in the treatment of HER2-positive
breast cancer has a half-life of 24 h (51) whilst the monoclonal
HER2 antibody trastuzumab also used in HER2-positive breast
cancer has a half-life of over 5 days (52). Drugs with a shorter half-
life will have to be dealt with carefully to ensure that cancer cells
receive the maximal benefit from drug dosing. Also drugs with a
long half-life should be removed from cells long before the models
are to be used in experiments. This ensures that residual drug will
not remain in the cells and effect proliferation assays comparing
survival between the parental and resistant cells.
Optimization of treatment dose in parental cell line
The dose of drug used must be optimized for the parental cell line
selected for use in developing the resistant model. A cytotoxicity
assay in the parental cell line can be used to determine a suitable
dose range. This dose range can then be compared to the pharma-
cokinetic information for the drug of interest. The rate of recovery
from drug treatment is just as important as the IC50; as the rate
of recovery can be different between agents even if an equiva-
lently cytotoxic dose is administered to cells. Figure 1 shows the
recovery of two ovarian cancer cell lines (OVCAR8 and UPN251)
from equivalently cytotoxic doses of carboplatin and paclitaxel.
The recovery from paclitaxel is much faster than carboplatin.
The chemotherapeutic drug paclitaxel is frequently given at a
dose of 175 mg/m2 as a single agent (53, 54). Pharmacokinetic
studies for this dose show peak-plasma concentrations as high
as 10,000 ng/mL but drop off quickly after 24 h to 50 ng/mL and
below (55, 56). In the development of platinum/taxane-resistant
OVCAR8 and UPN251 ovarian cancer cells, treatment doses were
chosen trailed over the range of IC20–IC80, and were consistent
with doses used in the clinical setting. Paclitaxel doses tested for
OVCAR8 and UPN251 were from a range of 2.3–14 and 10–
100 ng/mL. Carboplatin doses tested for OVCAR8 and UPN251
were 2.3–18.5 and 0.7–2µg/mL, respectively. The final chosen
FIGURE 1 | Recovery of OVCAR8 and UPN251 from carboplatin or
paclitaxel treatment. 1×104 cells were treated for 3 days with the
indicated doses of either carboplatin or paclitaxel and recovery monitored
as described in Section “Methods.”
doses of paclitaxel and carboplatin displayed an initially large
percentage cell death or growth inhibition compared to a control
grown in drug-free media. Carboplatin doses of 4 and 2µg/mL
and paclitaxel doses of 12 and 60 ng/mL were chosen for OVCAR8
and UPN251, respectively (Figure 1). After treatment with the
selected doses and removal of the drug, the cells were able to return
to logarithmic growth ensuring the selection of resistant cell sub
populations.
In the development of platinum-resistant H69 small cell lung
cancer (SCLC) cells, treatment doses were chosen in the range of
IC10–IC40, and were consistent with doses used in the clinical set-
ting (19). Two exposure times and doses were used for cisplatin
and oxaliplatin reflecting differing pharmacokinetic phases of the
administration of platinum drugs; 2-h treatments at 1–8µg/mL
and 4-day treatments at 0.2–1.6µg/mL. The lowest drug concen-
tration treatments all produced 20–30% cell death and growth
arrest in H69 cells. Drug-treated cells increased in size and did
not aggregate in typical SCLC clumping morphology. Surviving
cultures were then retreated when their normal growth rate and
clumping morphology had returned, ~3–4 weeks later.
POPULATION DYNAMICS
In most selection strategies the whole population of cells remains
as one group throughout the selection, no cloning or other separa-
tion methods are used. If a pulse of drug is given,a small percentage
of cells remain, which repopulates the flask. This new population
of cells is then retreated with the next pulse (18, 19). Alternatively
a low-level of drug is present continuously, the cells adapt to grow-
ing in the presence of the drug and then the dose of drug is slowly
increased (25).
It is well known that tumors are heterogeneous (57–59). Con-
sequently, the cancer cell lines derived from tumors are also het-
erogeneous. For example, breast tumors from patients who are
BRCA1/2 carriers have been shown to be heterogeneous, where
not all cells have lost the second BRCA1/2 allele (60). Selection
with chemotherapy agents therefore often result in the isolation
of a cell population that already exists in the culture. Indeed,
this has been demonstrated for many drug-resistant models, par-
ticularly in projects, which examine cancer stem cells (CSCs).
CSCs are thought to be responsible for tumor regeneration after
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chemotherapy. Drug-resistant cell lines are often enriched for
markers of stem cells. The stem-cell marker CD133 was found
to be enriched in a panel of cisplatin-resistant lung cancer cell
lines, with a 5-fold increase in both A549CisR and MORCisR, and
a 12-fold increase in H460CisR cells (61).
There are other physical methods of separation available to
select different populations from a cell line such as limited dilu-
tion or cell sorting by flow cytometry. This can isolate cells which
may be more resistant to chemotherapy than other populations
within the same cell line (62). The advantage of clonal populations
as drug-resistant models for is that there is no drug treatment is
required and the resulting model is more stable. The disadvan-
tages however are that many clones must be established and there
is no guarantee that the clonal populations derived will display any
difference in drug resistance.
Clonal populations can be established by limited dilution. This
relies on the ability of the cells to grow independently of each
other, and as such may not be suitable for all cell lines. It involves
seeding cells at a very low density to result in one cell per well of a
96-well plate. Once the cells grow to confluency, they can be tested
as a clonal population. Another method to obtain clonal popula-
tions is cloning rings (62). Standard toxicity testing on the clonal
populations generated will show whether they display an inherent
resistance to the agent of interest.
A combination of drug treatment and cloning of cells has also
been used to produce resistant models. KB-8-5-11 colchicine-
resistant cells were developed from parental KB-3-1 cells by
selecting clones after three stepwise increases in colchicine drug
treatment (24). Clones 8, 5, and 11 were the successful clones
picked each round of the selection strategy.
Cloning can also be used to investigate heterogeneity within a
developed drug-resistant model. A human colon cancer cell line
(LoVo) was treated with cisplatin using a continuous exposure
ranging from 0.005 to 20.0µg/mL over 20 months in culture (63).
At the end of the treatment, two morphologically distinct sub-
populations were observed; these were then cloned by limiting
dilution. The subclones showed different patterns of cross resis-
tance to chemotherapy agents. The first clone overexpressed the
ABC efflux transporter P-glycoprotein (P-gp) and the other clone
did not. Heterogeneity was also seen in cisplatin-resistant models
developed from a human pancreatic cancer cell line with a muta-
tion in DNA repair protein BRCA2. Fourteen cisplatin-resistant
clones were obtained. In 7 of 14 clones, the functionality of BRCA2
had been restored by secondary mutations, the remaining clones
still had a non-functional BRCA2 protein (64).
RISK-REDUCTION STRATEGIES: COMPARATIVE SELECTION
It is reasonably common to have difficulties developing resistance
or to produce drug-treated daughter cell lines which have not
increased in resistance relative to the parental cell line. Selection
strategies which do not produce drug resistance are interesting
from a clinical perspective as this is what we want to achieve for
cancer patients. Unfortunately, failures to develop drug resistance
are generally not reported in the literature.
As a risk-reduction strategy, a comparative selection strategy
should be performed, where selection of multiple cell lines or
multiple chemotherapeutic agents are performed in parallel in
FIGURE 2 | Comparative selection of drug-resistant cell lines. (A) Plan
for selection of two parent cell lines with two different drugs to produce
four drug-resistant daughter cell lines. (B) Plan for selection of one parent
cell line with two drugs at different doses or treatment intervals, producing
four drug-resistant daughter cell lines.
the laboratory. Figure 2A shows a strategy where two parental
cell lines are each treated with two chemotherapy agents, produc-
ing four different daughter cell lines. Figure 2B shows one parental
cell line being treated with two chemotherapy agents, in two differ-
ent doses or intervals producing four different daughter cell lines.
By using a comparative development strategy, it is hoped that at
least one of them will successfully produce a stable drug-resistant
model. It can be interesting to observe which strategies produced
resistance and which did not. These may be useful observations
for the clinical treatment of cancer.
An example of a comparative selection strategy used H69 SCLC
cells treated with cisplatin or oxaliplatin for two time periods, 2 h
or 4 days. The 4-day pulse selection produced more stable resis-
tance than the 2-h pulse (19) (Table 2). Had only the 2-h pulsed
treatment been tested in this model drug resistance would have
not been developed. The comparative nature of the selection also
led to the finding that oxaliplatin resistance developed faster than
cisplatin resistance in H69 cells (19).
A large study by Tegze et al. aimed to develop 40 drug-resistant
models from MCF-7 and MDA-MB-231 breast cancer cells using
doxorubicin and paclitaxel as selecting agents. They succeeded in
making 29 drug-resistant models, 10 doxorubicin and 4 paclitaxel-
resistant MCF-7 cell lines, and 6 doxorubicin and 9 paclitaxel-
resistant MDA-MB-231 cell lines. From this study it appears that
paclitaxel resistance was easier to develop in MDA-MB-231 (ER-
negative) cells and doxorubicin resistance was easier to develop in
MCF-7 (ER-positive) cells.
A study by our group (18) developed resistance to paclitaxel
and carboplatin in large cell lung cancer cell lines (H1299 and
H460). Cells at low confluence in 75cm2 flasks were exposed
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to 50µg/mL carboplatin and 150 ng/mL (H1299) or 50 ng/mL
(H460) paclitaxel for 4 h. After this period, the drug was removed
and the flasks were rinsed and fed with fresh complete media. The
cells were then grown in drug-free media for 6 days, replenish-
ing the media every 2–3 days. This was repeated once a week for
10 weeks. Table 4 shows the IC50s of the platinum and taxane-
resistant cell lines to a variety of chemotherapy agents. Resistance
in the carboplatin-selected cells (1.5–2.3-fold) was considerably
less than the resistance obtained in the paclitaxel-selected cells
(2.4–4.4-fold). Selected cell lines show no obvious cross resis-
tance pattern except within families of drugs, e.g., paclitaxel and
docetaxel; carboplatin and cisplatin. The TAX-selected cells were
also found to be resistant to vincristine, which is unsurprising
since both agents affect microtubules. Both carboplatin-selected
cell lines had a modest but statistically significant increased resis-
tance to paclitaxel. The different patterns of resistance in cell lines
selected under similar conditions show the complicated nature of
Table 4 | Fold resistance of H1299 and H460 resistant variants
compared with their parental cell lines.
Chemotherapeutic
agent
H1299-cpt H1299-txl H460-cpt H460-txl
Carboplatin 2.0** 1.7*** 2.3* 0.8*
Cisplatin 1.5* 1.5 1.6 0.7
5-FU 1.0 1.8** 0.9 1.1
VP-16 1.4** 1.1 0.9 1
Vincristine 0.8* 2.3* 2.9*** 2.5
Adriamycin 0.9 1 1 0.9
Paclitaxel 1.2* 4.4*** 1.6*** 2.4***
Docetaxel 0.6 2.5*** 2.3 2.8***
*p-Value <0.05; **p-value <0.01; ***p-value <0.005.
multiple-drug resistance. For example, H1299-cpt became sensi-
tive to vincristine, while after identical drug treatment, H460-cpt
developed significant resistance to vincristine (2.9-fold). Over-
all, the low-level resistance (two- to five-fold) observed in these
selected cell lines may be more clinically relevant to study than
higher levels of resistance and this study highlights the importance
to studying mechanisms in multiple models to identify relevant
pathways.
If a selection strategy fails to develop resistance, the treatment
conditions can be altered in an attempt to produce higher levels of
resistance. If the cells are growing very well after drug treatment,
consider dose escalation. In some cases this may push the dose
used above clinically relevant levels but it will increase the chance
of resistance developing. Alternatively, the length of time the cells
are exposed to drug can be increased or a pulsed-selection strategy
could be converted to a continuous selection strategy. This may
make the model less clinically relevant but may produce resistance
that can be studied in the laboratory.
CASE STUDIES OF DRUG-RESISTANT CELL LINES
The following section presents two case studies of drug-resistant
cell lines developed in our laboratory, the reasons that selection
conditions were chosen and the drug resistance outcomes of the
developed cell lines. A case study using continuous selection is
presented for lapatinib in breast cancer. A case study using pulsed
selection is presented for temozolomide-resistant melanoma.
LAPATINIB-RESISTANT BREAST CANCER CELLS – CONTINUOUS
SELECTION
Of the published models of acquired lapatinib resistance there is
very little commonality in the procedures used to condition the
cells, in either the concentrations of lapatinib used or in the deter-
mination of resistance status (Table 5) (65–72). For instance, the
procedures used to develop models of acquired lapatinib resistance
Table 5 | Published cell line models of acquired lapatinib resistance, the method and concentration used to condition the cells and the proposed
mechanism of lapatinib resistance.
Parent cell line Conditioning method Lapatinib concentration Profiling technique Resistance mechanism Reference
BT474 Single cell cloning 5µMa Affymetrix array Upregulation of ER signaling (65)
BT474, SKBR3 Single cell cloning 5µMa Affymetrix array Activation of RelA (66)
SUM190 Continuous exposure (0.25–2.5µM) Immunoblotting Overexpression of XIAP (67)
BT474 Single cell cloning 3µMa phospho-tyrosine
immunoblotting
Overexpression of AXL (68)
HCT116 Continuous exposure 10µMa Immunoblotting Increased expression
of MCL-1
(69)
HCC1954, BT474 Continuous exposure (0.1–1µM) Immunoblotting Increased expression
of β1-integrin
(70)
SKBR3, MDA-MB-361,
UACC893, BT474,
HCC1954, SUM190
Continuous exposure Increasing concentration
up to 1 or 2µM
Phospho-proteomic
profiling
Increased SRC kinase activity (71)
BT474, UACC812 Continuous exposure (0.1–1µM) Immunoblotting Upregulation of ER signaling (72)
aDenotes greater than peak-plasma concentration (2.5µM).
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included a single cell cloning technique (65, 68) fixed dose condi-
tioning (69) and dose escalation conditioning (67, 71, 72). There
was significant variation in the concentrations of lapatinib used to
condition the cells; many studies began with a low dose of lapatinib
(e.g., 100 nM) which was dose-escalated to upwards of 2µM. Fixed
concentration conditioning was performed with concentrations
of lapatinib ranging from 3 to 10µM. The length of conditioning
required to achieve resistance varied from study to study with the
majority of studies taking ~12 weeks to achieve resistance, whereas
other studies took up to 1 year to achieve resistance. Another varia-
tion in different models of lapatinib resistance was the definition of
lapatinib resistance. Most of the studies defined their conditioned
cell lines as resistant based on their ability to grow in the presence
of the concentration of lapatinib used to condition the cells, only
one study used an IC50 method while a number of studies did not
quantify the level of resistance. In contrast to the previously pub-
lished models of acquired lapatinib resistance, the resistant models
developed by us use a relatively low dose of lapatinib relative to
the IC50 of the resulting cell line. To our knowledge our model of
acquired lapatinib resistance, HCC1954-L are the first to show that
extended exposure to low dose lapatinib results in significant lap-
atinib resistance, with resulting lapatinib IC50 values significantly
higher than the concentration used for conditioning.
HCC1954 cells overexpress HER2 (73) and therefore represent a
cell line model of HER2-positive breast cancer. Lapatinib is a tyro-
sine kinase inhibitor that targets the intracellular domain of HER2
and EGFR and is approved for the treatment of HER2-positive
breast cancer (74, 75). HCC1954 are moderately sensitive to lap-
atinib with an IC50 of 0.43± 0.03µM (Figure 3A). Lapatinib is
administered to cancer patients orally with a dose of 1000–1250 mg
given daily (76). The median peak-plasma concentration of lapa-
tinib reported in patients receiving 1200 mg lapatinib (once daily)
was 1.2µg/mL (2.1µM) and the median steady-state trough con-
centration was 0.3µg/mL (0.5µM), with a range of 0.2–0.5µg/mL
(77). Therefore a continuous selection strategy is clinically relevant
for lapatinib. To optimize the dose of drug used for selection, a lap-
atinib dose response assay was performed in order to determine the
concentration of lapatinib which would result in 70% growth inhi-
bition over a 4-day treatment. Treatment of HCC1954 cells with
1µM lapatinib inhibited the growth of the cells by 71.5± 1.2%
compared to untreated controls (p= 0.004) (Figure 3B). There-
fore a selection strategy of continuous exposure of HCC1954 to
1µM lapatinib was initiated with the media replenished every
4 days with fresh drug. The selection strategy was conducted in
duplicate with “A” and “B” flasks as a backup in case there were
problems with one flask.
HCC1954 cells were seeded into two flasks; 1× 106 cells per
75cm2 flask. One flask was left untreated but was passaged along-
side the treatment flask and named HCC1954-par, the cells treated
with 1µM lapatinib were named HCC1954-L. It is important to
passage the untreated parental cells alongside the treated cells as a
control as continuous cell culture can result in alterations in cellu-
lar characteristics, including drug resistance. The morphology of
both cell lines and the sensitivity of the cell lines to lapatinib were
monitored throughout the selection. After 3 months of treatment,
the morphology of HCC1954-L was not altered (Figure 3C). For
all cytotoxicity assays the HCC1954-L cells were grown in drug-
free media for 5 days prior to testing. The lapatinib IC50 value
for the HCC1954-par cells was 0.42± 0.01µM, which is simi-
lar to the original HCC1954 cells. The lapatinib IC50 value for the
HCC1954-L cells was 0.75± 0.07µM (Figure 3D). This represents
1.8-fold increase in resistance to lapatinib. At this stage of the treat-
ment process the lapatinib IC50 of HCC1954-L cells had not yet
exceeded the treatment dose however they had begun to actively
proliferate in the presence of lapatinib. The concentration of lapa-
tinib was therefore increased from 1 to 1.25µM and conditioning
continued with this concentration for a further 3 months.
After 6 months of lapatinib conditioning, the sensitivity of the
cells was again tested. Both the “A” and “B” flasks of HCC1954-
L cells developed equivalent amounts of resistance, and the “As”
were chosen for all subsequent experiments and the “Bs” frozen
as a backup. The lapatinib IC50 value for the HCC1954-par cells
was 0.42± 0.02µM whereas the lapatinib IC50 for HCC1954-L
cells was 2.67± 0.08µM (p= 0.01) (Figure 3E). This represents
6.1-fold increase in resistance to lapatinib. HCC1954-L cells were
deemed to be resistant to lapatinib as the lapatinib IC50 was above
the 1µM threshold for lapatinib sensitivity (78). The resistant cells
also exhibited distinct morphological alterations compared to the
parental cell line. These differences were indicated by more distinct
colony boundaries and a flatter cell shape (Figure 3F).
In order to assess the stability of acquired resistance in the
HCC1954-L cell line, sensitivity to lapatinib was assessed after
freezing and thawing and following drug withdrawal. To establish
a reliable cell line model of lapatinib resistance the phenotype
must be stable when the cell line is frozen and re-thawed. To
assess this, frozen stocks of the HCC1954-par and HCC1954-
L cells were prepared in fetal calf serum containing 5% DMSO.
After a minimum of 48 h in liquid nitrogen the frozen stocks were
thawed and the viability of the stocks assessed by microscopy.
The cells were then passaged a minimum of 3 times before lapa-
tinib sensitivity assays were repeated (Figure 3G). The lapatinib
IC50 was 0.44± 0.02µM in the parental cells while the lapatinib
IC50 in HCC1954-L cells was 2.73± 0.05µM. This indicates that
the HCC1954-L cells retain their resistant phenotype following a
freeze/thaw cycle.
In order to access the long-term stability of the resistant phe-
notype, drug withdrawal assays were performed. Lapatinib was
removed from the HCC1954-L cells and the sensitivity of the cells
to lapatinib was tested at 4-week intervals for a period of 12 weeks,
the results at each interval are illustrated in (Figure 3G). Follow-
ing 12 weeks growth in the absence of lapatinib the lapatinib IC50
of the parental cells was 0.43± 0.05µM while the lapatinib IC50
of HCC1954-L cells was 2.63± 0.16µM. There was no significant
difference between the initial lapatinib IC50 for either the parental
or resistant cell line and the lapatinib IC50 for the cell lines after
12 weeks growth in the absence of lapatinib (Figure 3H).
Therefore, we successfully established a stable cell line of
acquired lapatinib resistance (HCC1954-L) induced by long-term
continuous treatment with sub-peak-plasma concentrations of
lapatinib. The mechanisms of acquired resistance to lapatinib are
being investigated in this model using proteomics and genomic
techniques.
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FIGURE 3 | Continuous selection of HCC1954 with lapatinib.
(A) Proliferation of HCC1954 cells following a 5-day treatment with
lapatinib. (B) HCC1954 cells treated with varying concentrations of
lapatinib over a 4-day period. Cell counts were performed using ViaCount
reagent and Guava Software and expressed relative to control untreated
cells. (C) Images of HCC1954-par and HCC1954-L cells after 3 months of
lapatinib conditioning at 100× magnification. (D) After 3 months
conditioning with 1µM lapatinib, the proliferation of HCC1954-par and
HCC1954-L cells was measured. (E) After 6 months conditioning with
lapatinib, the proliferation of HCC1954-par and HCC1954-L was assessed.
(F) Images of HCC1954-par and HCC1954-L cells after 6 months of lapatinib
conditioning at 200× magnification. (G) Sensitivity of HCC1954-par and
HCC1954-L cells to lapatinib following a freeze-thaw cycle. Growth is
expressed relative to untreated control cells. (H) Lapatinib IC50 values for
HCC1954-par and HCC1954-L cells following 1, 2, and 3 months growth in
the absence of lapatinib. All growth rates and IC50s were calculated
following a 5-day lapatinib treatment. Growth is expressed relative to
untreated control cells. All error bars represent the standard deviation of
triplicate experiments. Student’s t -test was performed to determine
significant differences: *p<0.05; **p<0.01.
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FIGURE 4 | Pulse selection of Malme-3M and HT144 with temozolomide. (A) Selection strategy of Malme-3M and HT144, each treatment of temozolomide
was performed in duplicate. Effect of temozolomide in Malme-3M and HT144 and temozolomide “pulse selected” resistant variants. (B) Malme-TMZ(A) and
Maleme-TMZ(B) vs. Malme-3M cells (C). HT144-TMZ vs. HT144 cells. Error bars represent the standard deviation of triplicate assays.
TEMOZOLOMIDE-RESISTANT MELANOMA CELL LINES – PULSED
SELECTION
Temozolomide is frequently used to treat metastatic melanoma.
No dosing schedule of temozolomide has been clinically proven
to be more effective than a single administration of temozolomide
(79); however current treatments favor a 5-day treatment schedule
(80). We found that the IC50 concentrations of temozolomide were
in the high micromolar range in melanoma cell lines. Previous
studies in two melanoma cell lines demonstrated temozolomide
IC50 concentrations of ~800µM (81), which is consistent with
the values observed in our cell line panel of six melanoma cell
lines (temozolomide IC50 ranged from 250 to 800µM). However,
in the clinical setting plasma levels of temozolomide only reach
concentrations approaching 80µM (82) The half-life of temozolo-
mide is <2 h (83), which would reduce the efficacy of the drug
in patients and may also explain the high IC50 values observed
in vitro. A pulsed selection of drug was chosen to mimic these
pharmacokinetic properties of temozolomide.
Malme-3M or HT144 melanoma cell lines were seeded at a
density of 2.5× 104 cells in a 75 cm2 flask. The entire selection
strategy was conducted in duplicate; two flasks of each cell line
were set up for untreated control flasks and two for temozolo-
mide selection (Figure 4A). Cells were allowed to attach for 24 h
prior to treatment with chemotherapy. For Malme-3M cells, after
each treatment cells were allowed to grow until confluent, then
trypsinised and reseeded at a density of 2.5× 104 cells per flask
for the next round of selection. For HT144 cells, cells were grown
in the flask for the 5 days of their treatment, then left to grow to
confluence. After cells recovered they were trypsinised reseeded at
2.5× 104 cells per flask for the next round of selection.
The Malme-3M cells were pulse treated with 300µM temozolo-
mide for 6 h and then the drug containing medium removed and
replaced with fresh drug-free medium. This single pulse treatment
was repeated six times. HT144 cells were treated for 6 h daily with
330µM temozolomide for 5 days. After the five daily treatments
the drug was removed and replaced with fresh drug-free media.
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This treatment was repeated four times. This treatment schedule
was used to replicate that of the clinical setting, where temo-
zolomide is administered daily for 5 days, followed by a period
of no treatment (84). The pulse selection strategy used in these
cells allowed us to compare differences between the clinical daily
administration and the lab based pulse selection to observe if either
regimen resulted in increased levels of resistance acquired.
The IC50 for temozolomide in Malme-3M parent cells is
306± 29µM. Malme-TMZ(A) and Malme-TMZ(B) display sig-
nificantly increased IC50s for temozolomide of 440± 21µM
[1.44-fold increase (p= 0.004)] and 515± 45µM [1.68-fold
increase (p= 0.04)] (Figure 4B). The IC50 for temozolomide
in HT144 cells is 338± 25µM. In HT144-TMZ(A), the pulse-
selected variant of HT144, the IC50 increased to 490± 15µM,
which represents a 1.45-fold increase in resistance to TMZ
(p= 0.002) (Figure 4C). HT144(B) did not develop significant
resistance to temozolomide, and so was not used in further studies.
During drug selection of cell lines, cells can acquire altered sen-
sitivity to other chemotherapeutic drugs. The two temozolomide-
selected cell lines from each parent cell line with the highest
levels of resistance [Malme-TMZ(B) and HT144(A)] were tested
with four drugs to examine the chemosensitivity between the
parent and the resistant cell lines (Table 6). The melanoma cell
line HT144 and the temozolomide-selected variant HT144-TMZ
display similar sensitivity to cisplatin and epirubicin whilst the
resistant cell line is significantly more sensitive to mitoxantrone
(p= 0.02). Malme-3M and the pulse-selected cell line Malme-
TMZ have similar IC50s for EPI and mitoxantrone. Malme-TMZ
is significantly more resistant to cisplatin (p= 0.001) and both
HT144-TMZ and Malme-TMZ are significantly more resistant
to docetaxel than the parent cell lines Malme-3M and HT144
(p= 0.02; p= 0.02), although the IC50 values are still in the very
low nanomolar range.
Two temozolomide-resistant cell lines [Malme-TMZ(B) and
HT144(A)] were established using two different selection meth-
ods. Duplicate selection proved useful in this selection strategy
as one of the variants HT144-TMZ(B) did not develop resis-
tance. Although the level of resistance induced was relatively low,
these two cell lines provide unique clinically relevant models to
study acquired temozolomide resistance in melanoma (85). The
temozolomide-resistant variants were cross resistant to cisplatin.
As temozolomide and cisplatin are both DNA damaging agents,
there may be common mechanisms of resistance to the DNA
damage induced by these agents.
Table 6 | Fold resistance of HT144 and Malme-3M resistant variants
compared with their parental cell lines.
Chemotherapeutic agent HT144-TMZ Malme-TMZ
Cisplatin (nM) 1.4 2.0*
Epirubicin (nM) 1.3 0.8
Mitoxantrone (nM) 0.2* 1.3
Docetaxel (nM) 1.4* 1.2*
*Indicates a p-value <0.05 as calculated by Student’s t-test.
MAINTAINING DRUG-RESISTANT CELL LINES FOR RESEARCH
Once resistance has been established with the selection strategy the
stability of the resistance needs to be determined. One important
test of the stability of the model is the recovery of the drug-resistant
phenotype from the frozen stocks. If the phenotype is lost or resis-
tance is significantly lower on freeze thaw then the model will not
be practical to use in the laboratory. If the resistance is not stable
on freeze thaw then the drug-resistant cells need to be treated for
longer, possibly with a higher dose of chemotherapeutic.
The long-term stability of resistance also needs to be examined.
Resistant cell models that have been selected by continuous expo-
sure to drug should be grown for several months to determine
if the resistance phenotype remains present. Some cell lines may
be completely stably resistant (Figure 5A) and are grown in the
absence of chemotherapeutic, such as DLKP-A or IGROVCDDP
(21, 25). Regular monitoring by cytotoxicity assay is required to
make sure that the resistance phenotype of the cell lines persists.
Alternatively, the cells can be grown continuously in
chemotherapeutic, either at the dose used in selection or a lower
maintenance dose. This may be if the cells are not stably resis-
tant on removal of the chemotherapeutic or if the researchers
wish to ensure consistency of experiments. KB-CP20 cisplatin-
resistant cells which were selected with increasing concentrations
of cisplatin up to 20µg/mL over a period of 6 months. The
FIGURE 5 | Maintaining drug-resistant cell lines in cell culture.
(A) Stable cell lines require no drug treatment to maintain their resistant
phenotype. (B) Some cell lines are grown continually in the presence of
chemotherapy, chemotherapy needs to be removed for one subculture prior
to using for experiments. (C) Some models are repeat pulse treated after a
certain number of passages or weeks in culture once their resistant
phenotype begins to fade. (D) Some models are discarded and new cells
grown from master stocks after a certain number of passages or weeks in
culture once their resistant phenotype begins to fade.
www.frontiersin.org March 2014 | Volume 4 | Article 40 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McDermott et al. Development of in vitro drug-resistant cancer cells
resistance was then maintained in media containing 5µg/mL
cisplatin (22). KB-5-8-11 colchicine-resistant cells are also main-
tained in 100 ng/mL of colchicine (24). Resistant cell models which
are maintained in chemotherapy drug need to be grown in drug-
free media for a passage prior to conducting experiments (86).
This is so that the drug-free controls of experiments are cells
not exposed to drug, rather than cells grown in the maintenance
dose of chemotherapy. Figure 5B shows a subculture schematic
for this technique. Another approach to maintaining stability is
growing cells in drug-free media but using a pulse treatment
at regular intervals (Figure 5C). This can be used even if the
cell model was originally developed by continuous exposure. The
CEM/E25 and CEM/E1000 epirubicin-resistant variants of CCRF-
CEM leukemia cells were established by continuous exposure then
grown without drug and resistance was maintained by repeat pulse
treatment every 6 weeks with the selecting doses of epirubicin 25
and 1000 ng/mL, respectively (15, 16).
Resistant models that are selected by pulse selection are often
less stable than their continuously selected counterparts. How-
ever, IGROVCDDP is a stably resistant cell line established by
pulse selection using dose escalation (21). Pulse-selected cell lines
which lose their resistant phenotype can also be maintained by re-
treatment with the selecting dose (Figure 5C) such as K562/DNR
resistant leukemia cells (17). Alternatively, instead of repeating the
pulse treatment, resistant cells can be grown for a certain num-
ber of weeks or passages and then new stocks are defrosted of an
earlier passage with the resistant phenotype present (Figure 5D).
H69CIS200 and H69OX400 cisplatin and oxaliplatin-resistant cells
were 1.5–2-fold resistant to platinums for 5–6 weeks in drug-free
culture and then the resistance phenotype faded over the next
6–8 weeks in culture (20). This technique is also often used with
resistant models regardless of selection strategy to ensure consis-
tency, so that cells within a limited range of passage numbers are
used for all experiments.
A REPRODUCIBLE EXPERIMENT?
Many mechanisms of resistance exist for each chemotherapy drug.
The chemotherapeutic drug cisplatin has been studied in drug-
resistant cell models for many years and mechanisms of resistance
include decreased accumulation of drug, inactivation by glu-
tathione and increased DNA repair (87). These mechanisms need
not all occur in the same drug-resistant model. Over time more
common mechanisms will be identified by their occurrence in
many drug-resistant models.
A comparative selection strategy could involve parallel selec-
tions of the same parental cell line with the same chemotherapy
agent, under the same treatment conditions. Similar or differ-
ent mechanisms could develop in these independent treatments.
This is the randomness of natural selection. A study by Tegze
et al. developed multiple drug-resistant cell lines from MCF-7 and
MDA-MB-231 breast cancer cells (88). The parent cell lines were
split and new cell lines were generated in parallel by treatment
with gradually increasing concentration of doxorubicin or pacli-
taxel. The study aimed to produce 10 resistant sublines for each
agent in each parent cell line. Using a continuous treatment strat-
egy they produced 29 resistant models over an 18-month period.
There were 10 doxorubicin and 4 paclitaxel-resistant MCF-7 cell
lines and 6 doxorubicin and 9 paclitaxel-resistant MDA-MB-231
cell lines. The fold resistance values compared to the parental cell
lines show up to 46- and 28-fold resistance to doxorubicin and
paclitaxel, respectively. The cell lines turned out to be highly het-
erogeneous for the mechanisms of drug resistance present, and in
general only a few mechanisms are activated in one cell line to
achieve drug resistance. Of note, the expression of P-gp did not
correlate with resistance in the cell line models, despite the devel-
opment of models with two P-gp substrates. This suggests that
in some of the models P-gp was activated early in the selection
process and became a dominant mechanism, in others this did not
occur.
Two models of cisplatin resistance were developed from H69
SCLC cells in the same research group in successive years (19,
89). These models were developed independently rather than in
parallel. H69-CP and H69CIS200 were developed with 100 or
200 ng/mL of cisplatin, respectively. Both cell models were two-
to four-fold resistant to cisplatin, and had decreased expression
of p21 which may increase the cell’s ability to progress through
the cell cycle in the presence of DNA damage. Both the H69-
CP and H69CIS200 cells showed no decrease in cellular cisplatin
accumulation. However, the H69-CP cells have increased levels of
cellular glutathione and are cross resistant to radiation whereas
the H69CIS200 cells have neither of these changes.
The cell line IGROV-1 has been used to develop cisplatin
drug-resistant models by many research groups. IGROVCDDP
cisplatin-resistant cells have an unusual resistant phenotype; they
are cross resistant to paclitaxel as they overexpress P-gp (90). It
is unusual but not unprecedented to see a model of acquired cis-
platin resistance overexpress P-gp (63, 91–94). This most likely
represents a generalized stress response to long-term cisplatin
treatment as cisplatin is not a P-gp substrate (95). IGROVCDDP
cells do not have increased total cellular glutathione but the
way glutathione is recycled within and from outside the cell is
enhanced, increased enzyme activity of glutathione reductase and
gamma-glutamyltransferase 1 (GGT1) was present (90). In con-
trast, IGROV-1/Pt0.5 and IGROV-1/Pt1, platinum-resistant cell
lines are sensitive to P-gp substrates, have increased cellular glu-
tathione and decreased GGT1 (96) which is the reverse pattern
to that seen in the IGROVCDDP platinum/taxane-resistant cells.
However, it should be noted, that different research groups can of
course have different sub clones of a parent cell line and this can
be a factor for the differences in the resistant models produced.
These examples demonstrate that the same cell line, treated with
the same chemotherapy agent leads to the development of a het-
erogeneous range of drug-resistant models. Therefore, the devel-
opment of drug-resistant models should be regarded as a process
rather than an experiment that can be repeated in biological trip-
licate. If parallel models of the same treatment are produced the
heterogeneity between drug-resistant cell lines should be exam-
ined with interest rather than dismissed as a non-reproducible
experiment.
CONCLUSION
We have provided a detailed guide to the decision-making process
for the development and ongoing maintenance of drug-resistant
cancer cell lines. There is no one right way to make drug-resistant
Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs March 2014 | Volume 4 | Article 40 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McDermott et al. Development of in vitro drug-resistant cancer cells
cell lines. The case studies from our laboratories highlight how we
have successfully developed models in a variety of ways for use in
research projects.
METHODS
CELL CULTURE
H1299, H460, HCC1954, Malme-3M, OVCAR8, UPN251, and
cells and their drug-resistant variants were grown in antibiotic and
chemotherapy-free RPMI (Sigma #R8758). HT144 cells and their
resistant variants were grown in antibiotic and chemotherapy-
free McCoys 5A medium (Sigma). HT144, HCC1954, Malme-
3M, OVCAR8, and UPN251 and their resistant variants were
supplemented with 10% FCS (Lonza, Belgium). H1299, H460,
and their resistant variants were supplemented with 5% FCS.
All cell lines were maintained in a humidified atmosphere with
5% CO2 at 37°C. All cultures were tested routinely and were
mycoplasma-free.
GROWTH CURVES FOR OPTIMIZATION OF SELECTION DOSES
OVCAR8 or UPN251 cells were plated in duplicate into 6-well
plates at a cell density of 1× 104 cells/mL in 1 mL media. A con-
trol plate was set up separately with duplicate wells. On day 2
1 mL of media with drug was added to all plates excluding the
control, which received drug-free media to the same volume. On
day 5 media was changed on all plates and replaced with drug-free
media. The control plate and one drugged plate were taken down
and cell counted. Cell counts for the control were compared to the
drug treatment. A percentage cell survival was calculated in order
to see the effects of drug treatment on cell growth/survival.
Percentage cell survival
= Average cell number of drugged cells
Average control cell number
× 100
Over subsequent days one plate for each drug dose was observed
under a light microscope to see when normal growth had returned.
When cells were deemed to have returned to confluence this plate
was cell counted to confirm recovery. Percentage cell survival will
now be above or climbing to 100%. The time taken for cells to
resume growth and return to confluence was recorded.
CYTOTOXICITY ASSAYS
To determine the cytotoxicity of chemotherapy drugs, cell
growth/viability was measured using an acid phosphatase assay;
1.5–3× 103 cells were seeded in flat-bottomed 96-well plates and
incubated overnight prior to addition of drug. Chemotherapeu-
tics were obtained from St Vincent’s University Hospital, Dublin,
Ireland. Lapatinib was purchased from Sequoia. Temozolomide
was obtained from the National Cancer Institute. Other inhibitors
and modulators were obtained from Sigma. Drug-free controls
were included in each assay. Plates were incubated for a further 5
(HCC1954, Malme-3M and HT144) or 7 days (H1299 and H460)
at 37°C in a humidified atmosphere with 5% CO2 and cell viability
was determined using an acid phosphatase assay (97). Growth of
drug-treated cells was calculated relative to control untreated cells
in biological triplicate.
STATISTICS
All experiments were performed at minimum in triplicate. Two-
sample, two-tailed Student’s t -tests were used to determine
significant differences using p< 0.05 as a cut off.
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